Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy.
Adoptive T cell immunotherapy
T cell receptor repertoire
bladder cancer
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
11
2020
accepted:
01
02
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
Recurrence and progression of non-muscle-invasive bladder cancer (NMIBC), frequent despite the availability of multiple treatment modalities, may be partly explained by the presence of immunosuppressive cell populations. We hypothesized that progression of disease could be prevented by the administration of an activated T cell immunotherapy (ACT) at time points when immunosuppressive populations increased in peripheral blood. In an N-of-1 study, a patient with multiple primary bladder high grade urothelial carcinomas, previously treated with standard local resection and chemotherapy but with evidence of progression, received ACT consisting of dendritic cells mixed with cytokine induced killer cells (DC/CIK), intravenously 18 times over a 6 year period at indicated time of observed increases in peripheral blood immunosuppressive CD8
Types de publication
Journal Article
Langues
eng
Pagination
1709-1718Informations de copyright
AJCR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
Cancer Res. 2019 Dec 15;79(24):6166-6177
pubmed: 31615807
Front Oncol. 2019 Nov 20;9:1270
pubmed: 31824850
J Math Biol. 2013 Dec;67(6-7):1339-68
pubmed: 23007599
Clin Transl Oncol. 2016 Jan;18(1):82-7
pubmed: 26266766
Blood. 2009 Nov 5;114(19):4099-107
pubmed: 19706884
Clin Cancer Res. 2014 May 1;20(9):2424-32
pubmed: 24583799
Clin Transl Oncol. 2013 Oct;15(10):780-8
pubmed: 23359185
Cancer Immunol Immunother. 2013 Jun;62(6):1123-30
pubmed: 23604172
Oncoimmunology. 2016 Dec 7;6(4):e1264563
pubmed: 28507788
Expert Rev Anticancer Ther. 2021 Mar;21(3):299-313
pubmed: 33249937
J Urol. 1997 Jul;158(1):62-7
pubmed: 9186324
Clin Transl Oncol. 2019 Jun;21(6):721-728
pubmed: 30374838
Drug Des Devel Ther. 2018 Jan 23;12:209-215
pubmed: 29416316
Springerplus. 2015 May 16;4:232
pubmed: 26020023
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13139-44
pubmed: 25157137
Int J Mol Sci. 2018 Jun 08;19(6):
pubmed: 29890703
Cytotherapy. 2018 Jan;20(1):126-133
pubmed: 28988693
Clin Cancer Res. 2019 Mar 1;25(5):1494-1504
pubmed: 30514775
Mol Oncol. 2019 May;13(5):1092-1109
pubmed: 30747484
Nat Med. 2016 Apr;22(4):433-8
pubmed: 26901407
Clin Cancer Res. 2017 Sep 1;23(17):5066-5073
pubmed: 28611200
Cancer Immunol Immunother. 2014 Sep;63(9):939-46
pubmed: 24916038
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Transl Med. 2019 Mar 28;17(1):101
pubmed: 30922329
J Immunother Cancer. 2018 Apr 4;6(1):24
pubmed: 29618376
World J Surg Oncol. 2018 Oct 2;16(1):197
pubmed: 30285788
Oncol Lett. 2013 Apr;5(4):1427-1429
pubmed: 23599807